Trial Profile
NABGEM study: A nationwide open-label multi-center prospective cohort study of nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 01 Aug 2021
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- Acronyms NABGEM prospective cohort study in LAPC
- 22 Mar 2017 New trial record